Clinical trial
A Phase 2 Multicenter Study of the Combination Zanubrutinib, Bendamustine, and Rituximab in Previously Untreated Waldenström Macroglobulinemia (ZEBRA Trial)
NCT06561347 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter Study of the Combination Zanubrutinib, Bendamustine, and Rituximab in Previously Untreated Waldenström Macroglobulinemia (ZEBRA Trial)
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 20, 2024
- Completion date
- December 1, 2027
- Enrollment
- 65 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.